ClinicalTrials.gg
CompletedNCT05966272Updated May 7, 2025

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

A Phase 2 interventional study of HRS9531 injection and HRS9531 injection Placebo in Type 2 Diabetes, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ribupatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. ribupatide · Diabetes Mellitus, Type 2.

Enrollment
4th of 11
199 · median 72
Started
2023
with 1 other
Phase 2
Only one
of the 11
Registered
4th of 11
by date
Lead sponsor
11 of 11
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is the only one in phase 2, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 11 studies testing ribupatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ribupatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects ,18-65 years of age, agreed and signed the
  2. Type 2 diabetes mellitus diagnosed for at least 6 months before the screening visit.
  3. Treated with conventional lifestyle intervention and stable treatment with metformin (≥1000 mg/day) at least 8 weeks prior to screening.
  4. 7.5-10.5% (both inclusive) at screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any results in examination at screening visit.
  2. Uncontrollable hypertension.
  3. A history of type 1 diabetes, specific diabetes, or secondary diabetes.
  4. Acute diabetic complications or severe hypoglycemia events within 12 months prior to screening.
  5. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening.
  6. Any organ-system developed within 5 years except for cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  7. Present or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other more serious mental illness.
  8. Surgery is planned during the trial.
  9. Mentally incapacitated or speech-impaired.
  10. Pregnant or lactating woman.
  11. In the investigator's judgment, there were circumstances that affected subject safety or otherwise interfered with the evaluation of results.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    Treatment group A

    HRS9531 injection dose level 1

    Drug: HRS9531 injection

  • Experimental
    Treatment group B

    HRS9531 injection dose level 2

    Drug: HRS9531 injection

  • Experimental
    Treatment group C

    HRS9531 injection dose level 3

    Drug: HRS9531 injection

  • Experimental
    Treatment group D

    HRS9531 injection dose level 4

    Drug: HRS9531 injection

  • Placebo comparator
    Treatment group E

    HRS9531 injection Placebo dose level 1

    Drug: HRS9531 injection Placebo

  • Placebo comparator
    Treatment group F

    HRS9531 injection Placebo dose level 2

    Drug: HRS9531 injection Placebo

  • Placebo comparator
    Treatment group G

    HRS9531 injection Placebo dose level 3

    Drug: HRS9531 injection Placebo

  • Placebo comparator
    Treatment group H

    HRS9531 injection Placebo dose level 4

    Drug: HRS9531 injection Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c after 20 weeks of treatment

    Time frame: Week 0 to Week 20

Secondary outcomes

  1. Proportion of subjects reaching HbA1c targets (HbA1c<7.0%) after 20 weeks of treatment

    Time frame: Week 0 to Week 20

  2. Proportion of subjects reaching HbA1c targets (HbA1c<7.0%) after 32 weeks of treatment

    Time frame: Week 0 to Week 32

  3. Change From Baseline in HbA1c after 32 weeks

    Time frame: Week 0 to Week 32

  4. Change from baseline in fasting plasma glucose (FPG), serum insulin and C-peptide after 20 weeks of treatment

    Time frame: Week 0 to Week 20

  5. Change from baseline in fasting plasma glucose (FPG), serum insulin and C-peptide after 32 weeks of treatment

    Time frame: Week 0 to Week 32

  6. Change from baseline body Weight and waist circumference after 20 weeks of treatment

    Time frame: Week 0 to Week 20

  7. Change from baseline in body Weight and waist circumference after 32 weeks of treatment

    Time frame: Week 0 to Week 32

  8. Number of Participants With Anti-HRS9531 Antibody

    Time frame: Week 0 to Week 36

  9. Number of AEs During the Trial

    Time frame: Week 0 to Week 36

07

Study locations

1 site
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Sep 2024, 13 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Jul 28, 2023
StartActual
Aug 12, 2023
Primary completionActual
Sep 24, 2024
CompletionActual
Sep 24, 2024
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05966272
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Aug 12, 2023
Primary completion
Sep 24, 2024
Completion
Sep 24, 2024
Last update
May 7, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion